GENMARK DIAGNOSTICS INC's ticker is GNMK and the CUSIP is 372309104. A total of 112 filers reported holding GENMARK DIAGNOSTICS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $196,000 | +1.6% | 13,403 | -1.1% | 0.01% | -11.1% |
| Q3 2020 | $193,000 | -34.8% | 13,557 | -32.5% | 0.01% | -40.0% |
| Q2 2020 | $296,000 | +21.8% | 20,093 | -66.0% | 0.02% | 0.0% |
| Q1 2020 | $243,000 | +32.8% | 59,083 | +55.1% | 0.02% | +66.7% |
| Q4 2019 | $183,000 | -20.8% | 38,104 | 0.0% | 0.01% | -25.0% |
| Q3 2019 | $231,000 | -6.5% | 38,104 | 0.0% | 0.01% | -7.7% |
| Q2 2019 | $247,000 | 0.0% | 38,104 | +9.4% | 0.01% | 0.0% |
| Q1 2019 | $247,000 | +4.7% | 34,819 | -28.2% | 0.01% | 0.0% |
| Q4 2018 | $236,000 | -29.8% | 48,475 | +5.9% | 0.01% | -23.5% |
| Q3 2018 | $336,000 | +11.6% | 45,775 | -3.1% | 0.02% | +6.2% |
| Q2 2018 | $301,000 | +17.6% | 47,250 | +0.3% | 0.02% | +23.1% |
| Q1 2018 | $256,000 | +23.1% | 47,106 | -5.3% | 0.01% | +18.2% |
| Q4 2017 | $208,000 | -4.1% | 49,765 | +120.6% | 0.01% | -8.3% |
| Q3 2017 | $217,000 | – | 22,557 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEEDHAM INVESTMENT MANAGEMENT LLC | 1,443,400 | $5,947,000 | 1.68% |
| Casdin Capital, LLC | 3,365,000 | $13,864,000 | 1.47% |
| Lyon Street Capital, LLC | 191,656 | $790,000 | 1.26% |
| CADIAN CAPITAL MANAGEMENT, LP | 3,489,055 | $14,375,000 | 0.71% |
| Portolan Capital Management | 893,090 | $3,680,000 | 0.55% |
| Eversept Partners, LP | 524,257 | $2,159,939 | 0.54% |
| Bullseye Asset Management LLC | 78,961 | $325,000 | 0.39% |
| Parkman Healthcare Partners LLC | 200,000 | $824,000 | 0.38% |
| Granite Investment Partners, LLC | 757,878 | $3,122,000 | 0.20% |
| Bellevue Group AG | 2,411,926 | $9,937,000 | 0.19% |